About: Shattering barriers toward clinically meaningful MSC therapies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Shattering barriers toward clinically meaningful MSC therapies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Shattering barriers toward clinically meaningful MSC therapies
Creator	Levy, Oren Abdi, Reza Alhasan, Ali Almalik, Abdulaziz Alturki, Meshael Bhere, Deepak De Biasio, Michael Fallatah, Mohanad Heinelt, Martina Karp, Jeffrey Kuai, Rui Milton, Yuka Nissar, Nabeel Reeve, Brock Shah, Khalid Siren, Erika
topic	covid:687959aa46ad99efd81baefd9d27149a9cc86d92#this
Source	Medline; PMC
abstract	More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical application imaginable, including neurodegenerative and cardiac disorders, perianal fistulas, graft-versus-host disease, COVID-19, and cancer. Several companies have or are in the process of commercializing MSC-based therapies. However, most of the clinical-stage MSC therapies have been unable to meet primary efficacy end points. The innate therapeutic functions of MSCs administered to humans are not as robust as demonstrated in preclinical studies, and in general, the translation of cell-based therapy is impaired by a myriad of steps that introduce heterogeneity. In this review, we discuss the major clinical challenges with MSC therapies, the details of these challenges, and the potential bioengineering approaches that leverage the unique biology of MSCs to overcome the challenges and achieve more potent and versatile therapies.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.1126/sciadv.aba6884
bibo:pmid	32832666
has license	cc-by-nc
sha1sum (hex)	687959aa46ad99efd81baefd9d27149a9cc86d92
schema:url	https://doi.org/10.1126/sciadv.aba6884
resource representing a document's title	Shattering barriers toward clinically meaningful MSC therapies
has PubMed Central identifier	PMC7439491
has PubMed identifier	32832666
schema:publication	Sci Adv
resource representing a document's body	covid:687959aa46ad99efd81baefd9d27149a9cc86d92#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/687959aa46ad99efd81baefd9d27149a9cc86d92
is schema:about of	named entity 'Adv.' named entity 'efficacy' named entity 'potent' named entity 'therapies' named entity 'MSC' named entity 'COMPANIES' named entity 'therapies' named entity 'process' named entity 'More' named entity 'potential' named entity 'MSC' named entity 'therapy' named entity 'general' named entity 'perianal' named entity 'clinical trials' named entity 'A L' named entity 'heterogeneity' named entity 'clinically meaningful' named entity 'cardiac disorders' named entity 'neurodegenerative' named entity 'clinical-stage' named entity 'fistulas' named entity 'demonstrated' named entity 'bone marrow' named entity 'intravenously' named entity 'MSCs' named entity 'mechanism of action' named entity 'insulin' named entity 'double-blind, placebo-controlled' named entity 'MSCs' named entity 'stiffness' named entity 'stemness' named entity 'subcutaneous' named entity 'saline' named entity 'macrophages' named entity 'animal model' named entity 'biopsy' named entity 'positively correlated' named entity 'MSCs' named entity 'phase 1/2' named entity 'MSCs' named entity 'herpes simplex virus' named entity 'host immune responses' named entity 'systemic administration' named entity 'MSCs' named entity 'up-regulated' named entity 'iPSCs' named entity 'MSCs' named entity 'rodents' named entity '36 hours' named entity 'medicinal product' named entity 'cytokine secretion' named entity 'inflammation' named entity 'clinical studies' named entity 'glioblastoma' named entity 'MSCs' named entity 'route of administration' named entity 'Quality control' named entity 'phase 2 study' named entity 'cancer cells' named entity 'preclinical studies' named entity 'drug release' named entity 'hyaluronic acid' named entity 'MSCs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software